Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

7C2P

Structure of Egk Peptide

Summary for 7C2P
Entry DOI10.2210/pdb7c2p/pdb
DescriptorPlant defensing Egk (2 entities in total)
Functional Keywordsplant defensin, protein binding
Biological sourceElaeis guineensis
Total number of polymer chains4
Total formula weight21405.12
Authors
El Sahili, A. (deposition date: 2020-05-08, release date: 2020-09-09, Last modification date: 2023-11-29)
Primary citationOng, S.T.,Bajaj, S.,Tanner, M.R.,Chang, S.C.,Krishnarjuna, B.,Ng, X.R.,Morales, R.A.V.,Chen, M.W.,Luo, D.,Patel, D.,Yasmin, S.,Ng, J.J.H.,Zhuang, Z.,Nguyen, H.M.,El Sahili, A.,Lescar, J.,Patil, R.,Charman, S.A.,Robins, E.G.,Goggi, J.L.,Tan, P.W.,Sadasivam, P.,Ramasamy, B.,Hartimath, S.V.,Dhawan, V.,Bednenko, J.,Colussi, P.,Wulff, H.,Pennington, M.W.,Kuyucak, S.,Norton, R.S.,Beeton, C.,Chandy, K.G.
Modulation of Lymphocyte Potassium Channel KV1.3 by Membrane-Penetrating, Joint-Targeting Immunomodulatory Plant Defensin.
Acs Pharmacol Transl Sci, 3:720-736, 2020
Cited by
PubMed Abstract: We describe a cysteine-rich, membrane-penetrating, joint-targeting, and remarkably stable peptide, EgK5, that modulates voltage-gated K1.3 potassium channels in T lymphocytes by a distinctive mechanism. EgK5 enters plasma membranes and binds to K1.3, causing current run-down by a phosphatidylinositol 4,5-bisphosphate-dependent mechanism. EgK5 exhibits selectivity for K1.3 over other channels, receptors, transporters, and enzymes. EgK5 suppresses antigen-triggered proliferation of effector memory T cells, a subset enriched among pathogenic autoreactive T cells in autoimmune disease. PET-CT imaging with F-labeled EgK5 shows accumulation of the peptide in large and small joints of rodents. In keeping with its arthrotropism, EgK5 treats disease in a rat model of rheumatoid arthritis. It was also effective in treating disease in a rat model of atopic dermatitis. No signs of toxicity are observed at 10-100 times the dose. EgK5 shows promise for clinical development as a therapeutic for autoimmune diseases.
PubMed: 32832873
DOI: 10.1021/acsptsci.0c00035
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.1 Å)
Structure validation

227111

数据于2024-11-06公开中

PDB statisticsPDBj update infoContact PDBjnumon